This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Genentech Seeks Approval of New Breast Cancer Drug Following Late-Stage Trial Win

SOUTH SAN FRANCISCO ( TheStreet) --The Genentech unit of Roche (RHHBY) announced positive top-line results from a phase III study of its experimental breast cancer drug T-DM1 that will allow the company to seek U.S. and European approval later this year.

Patients with advanced metastatic breast cancer treated with T-DM1 lived significantly longer without their disease getting worse compared to patients treated with GlaxoSmithKline's (GSK - Get Report) Tykerb, Genentech said. Final results for overall survival are not yet mature.

Detailed data from the phase III study, dubbed EMILIA, were withheld for presentation at a later medical meeting. Genentech said T-DM1's safety profile was "consistent" with previous studies of the drug.

All patients in the study were on their second line of treatment for breast cancer, having already been treated with Genentech's Herceptin and chemotherapy.

Based on these results, Genentech said it will submit T-DM1 for approval with the U.S. Food and Drug Administration later this year. Roche will seek European approval in the same time frame.

T-DM1 is a second-generation version of Genentech's blockbuster breast cancer drug Herceptin. The drug consists of Herceptin (also known as trastuzumab) linked to a tumor-killing chemotherapy payload developed by ImmunoGen (IMGN - Get Report).

If T-DM1 reaches the market, ImmunoGen will receive single-digit royalties pegged to the drug's sales by Genentech in the U.S. and Roche in the rest of the world.

At Thursday's closing price of $13.74, ImmunoGen's market value of $1.05 billion more than accounts for T-DM1 sales.

--Written by Adam Feuerstein in Boston.



>To contact the writer of this article, click here: Adam Feuerstein.

>To follow the writer on Twitter, go to http://twitter.com/adamfeuerstein.

>To submit a news tip, send an email to: tips@thestreet.com.

Follow TheStreet on Twitter and become a fan on Facebook.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
RHHBY $37.40 0.00%
GSK $44.79 0.00%
IMGN $9.02 0.00%
AAPL $131.78 0.00%
FB $80.14 0.00%

Markets

DOW 18,126.12 -36.87 -0.20%
S&P 500 2,120.79 -2.69 -0.13%
NASDAQ 5,097.9760 -8.6170 -0.17%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs